[ad_1]
Firm’s consolidated revenue after tax declined 26 p.c to Rs 173 crore for the fourth quarter ended March 31, 2022.
June 13, 2022 / 01:32 PM IST
Glenmark Pharma
Glenmark Pharma share value touched a 52-week low of Rs 375, falling over 3 p.c intraday, on June 13 on reviews of USFDA starting inspection of the corporate’s Baddi plant.
The US Meals and Drug Administration (USFDA) started inspection of Glenmark Pharma’s Baddi plant right this moment, sources confirmed to CNBC-TV18. The USFDA had issued a ‘Warning Letter’ in October 2019 to the Baddi facility.
The corporate’s consolidated revenue after tax declined 26 p.c to Rs 173 crore for the fourth quarter ended March 31, 2022. It reported a internet revenue of Rs 234 crore within the January-March interval of 2020-21 fiscal.
Consolidated revenues of the drug agency, nonetheless, rose to Rs 3,019 crore within the quarter below evaluation as in comparison with Rs 2,860 crore a 12 months in the past, recording a rise of 6 p.c on-year.
For the 12 months ended March 31, 2022, the Mumbai-based drug agency reported a PAT of Rs 994 crore, as towards Rs 970 crore in FY21.
At 1:18pm, Glenmark Pharma was quoting at Rs 379.50, down Rs 8.95, or 2.30 p.c, on the BSE. It was buying and selling with volumes of 27,883 shares, in comparison with its 5 day common of 75,453 shares, a lower of -63.05 p.c.
With inputs from PTI
[ad_2]
Source link